We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Laurimer Kuilan-Torres
Laurimer Kuilan-Torres
Products
PRODUCTS
Smith & Nephew, Inc.
Lane V. Christensen
and
Laurimer Kuilan-Torres
Price:
$117.00
View
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Dennis Cantellops
,
Laurimer Kuilan-Torres
, and
Marcus A. Ray
Price:
$117.00
View
Tianjin Asychem Pharmaceuticals Co., Ltd.
Laurimer Kuilan-Torres
Price:
$117.00
View
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Laurimer Kuilan-Torres
Price:
$117.00
View
Hangzhou Linkeweier Daily Chemicals Co., Ltd.
Laurimer Kuilan-Torres
Price:
$117.00
View
Jiangsu Excellence Medical Supplies Co., Ltd.
Laurimer Kuilan-Torres
Price:
$117.00
View
Bloomage Biotechnology Corp., Ltd.
Laurimer Kuilan-Torres
Price:
$117.00
View
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Laurimer Kuilan-Torres
Price:
$117.00
View
Ex-Lax, Inc.
Laurimer Kuilan-Torres
Price:
$117.00
View
Baxter Healthcare Corp.
Laurimer Kuilan-Torres
,
Miguel A. Martinez
, and
Jose E. Melendez
Price:
$117.00
View
View All Products by Laurimer Kuilan-Torres
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
